Method for chemoradiation therapy of malignant cerebral meningiomas

FIELD: medicine, oncology.

SUBSTANCE: the present innovation deals with adjuvant chemoradiation therapy of malignant cerebral meningiomas. In postsurgical period it is necessary to carry out lumbar puncture, catheterize subarachnoid space, sample 5 ml liquor, incubate liquor with cisplatin at the quantity of 0.1 mg in vitro at 38°C for 30 min to introduce it through a catheter into subarachnoid space. The procedure should be carried out twice at a 7-d-long interval, since the 2nd d of the beginning of this procedure it is necessary to conduct distance gamma-therapy at the bottom of removed tumor daily for 20 d up to total focal dosage being 60 Gy. The innovation enables to achieve stable remission, decrease toxicity of chemopreparation and frequency of side effects at considerable decrease of its cost price.

EFFECT: higher efficiency of therapy.

1 ex

 

The invention relates to medicine, namely to Oncology, and can be used for adjuvant chemoradiation therapy of malignant meningeal tumours of the Central nervous system.

A known method of using platinum drugs in Oncology, not only as cytostatic and radiosensibility, in doses much smaller therapeutic (Ayudarte et al. "Honey. radiology and radiation safety", 2004, vol 49, No. 6. p.23).

There is a method of treatment of malignant meningiomas brain combination with distantsionnoi gammagraphy (DHT) with systemic chemotherapy cisplatinum (A.v.kozlov "neurosurgery", 2001, No. 2, p.16), chosen as a prototype.

The disadvantages of the method of treatment of malignant meningiomas brain is the low efficacy and high toxicity of chemotherapy.

The aim of the invention is to increase the efficiency and reduce the toxicity of treatment of malignant meningiomas brain.

This objective is achieved in that in the postoperative period the patient perform a lumbar puncture, kateteriziruyut subarachnoid space, take 5 ml of the liquor, incubated liquor with cisplatin in an amount of 0.1 mg in vitro at a temperature of 38°C for 30 minutes and injected through the catheter into the subarachnoid shall prostranstvo, the procedure is carried out 2 times with an interval of 7 days. From the 2nd day start distantsionno gammagraphy (DHT) on the removed tumor bed daily for 20 days up to a total focal dose of 60 Gy.

The invention "Method chemoradiation therapy of malignant meningiomas brain" is new, as is unknown to the level of medicine in the field of chemoradiation therapy of malignant meningiomas brain.

The novelty of the invention lies in the fact that for the treatment of malignant meningiomas brain using the introduction of cisplatin on autorequire through endolyumbalno catheter in combination with DHT.

The invention is industrially applicable as it can be used in health care, in medical institutions for the treatment of patients with CNS tumours, cancer research institutes, breast care clinics and other clinical settings.

"The way chemoradiation therapy of malignant meningiomas brain" is as follows: in the postoperative period the patient perform a lumbar puncture needle (Tuohy, kateteriziruyut the subarachnoid space. Take the cerebrospinal fluid of a patient in an amount of 5 ml and incubated with cisplatin - 0.1 mg in vitro at a temperature of 38°C for 30 minutes, and then endolyumbalno administered to the patient. Procedure Khujand who are twice with an interval of 7 days. From the 2nd day start distantsionno the gamma-therapy is recommended on the removed tumor bed daily for 20 days up to a total focal dose of 60 Gy.

A specific example of the method chemoradiation therapy of malignant meningiomas brain

B-nd S-on, L.P., 67, n and/b - 3695/t, enrolled in the Department. INC RNII 22.03.2004 with a diagnosis of Anaplastic meningioma wings of the sphenoid bone to the left with increase in orbit. Condition after osteoplastic craniotomy with Subtotal removal of the tumor (3.02.2004, RSMU, g/a No. 1757-68/04 - anaplastic meningioma). Admission: moderate cerebral syndrome, mild exophthalmos left, moderate frontal psychopathological syndrome, Karnofsky index was 60%, General health status who is 2 points. On CT brain from 3.02-2004 is determined residual tumor in the left temporal region 8 by 4 by 4 cm left exophthalmos. With 22.03 on 27.04.2004 6-I have received a course of DHT to the total focal dose of 60 Gy with intrathecal by autolymphochemotherapy (ALHT) cisplatin at a dose of 0.2 mg between 06.2004 on 12.2004 6-I received 3 courses of intrathecal ALHT cisplatin at a dose of 0.2 mg Portability chemoradiation therapy satisfactory, complications and side effects were not decreased cerebral syndrome, decreased exophthalmos, Karnofsky index - 70%, General health status in the who - 2 the ball is and. On the control CT brain from 14.03.2005 is determined by reducing the size of the residual tumor in the virgin temporal region 5 3 3 see

Technical and economic efficiency of the method chemoradiation therapy of malignant meningiomas brain is that the use of cisplatin in endolyumbalno chemotherapy on autorequire in combination with distancing gamma-therapy is recommended on the bed of the removed tumor allows to achieve stable remission after resection of malignant meningiomas of the brain, to reduce the toxicity of cytostatic agents, the incidence of side effects and thus increase the effectiveness of chemotherapy while significantly reducing its cost.

The way chemoradiation therapy of malignant meningiomas of the brain, including endolyumbalno introduction of chemical, characterized in that in the postoperative period the patient perform a lumbar puncture, kateteriziruyut subarachnoid space, take 5 ml of the liquor, incubated liquor with cisplatin in an amount of 0.1 mg in vitro at a temperature of 38°C for 30 min and injected through the catheter into the subarachnoid space, the procedure is carried out 2 times with an interval of 7 days, from the 2nd day of the beginning of the procedures performed distantsionno the gamma-therapy is recommended on the removed tumor bed daily for 20 days to total focus is howling dose 60 Gr.



 

Same patents:

FIELD: organic chemistry, medicine, pharmacy.

SUBSTANCE: invention relates to geranyl compounds represented by the following formulas (I-1) , (I-2) or (I-3) wherein R1 means compounds of the following formulas: or R2 means a group remaining after removing all carboxyl groups presenting in carboxylic acid chosen from group consisting of malic acid, citric acid, succinic acid, fumaric acid and others; m = 1, 2 or 3; n = 0, 1 or 2, and m + n represent a number of carboxylic groups presenting in indicated carboxylic acid; R3 means p-hydroxyphenyl or mercapto-group. Also, invention relates to derivatives of mevalonic acid represented by the following formula (I-4): wherein R means -CH2OH or CH3. Also, invention to an antitumor agent comprising as an active component geranyl compound of formulas (I-1), (I-2) or (I-3) or derivative of mevalonic acid of the formula (I-4), and optionally a pharmaceutically acceptable carrier or solvent. Also, invention relates to a method for treatment of liver cancer based on using geranyl compound of formulas (I-1), (I-2) or (I-3), or derivative of mevalonic acid of the formula (I-4) and using proposed compounds in manufacturing an antitumor agent. Invention provides using geranyl compounds or derivatives of mevalonic acid as antitumor agents.

EFFECT: valuable medicinal properties of compounds and pharmaceutical composition.

7 cl, 3 tbl, 17 ex

FIELD: medicine, therapy.

SUBSTANCE: as a sclerotherapeutic preparation one should choose ethoxysclerol to carry out 1-2 courses of therapy at intervals between the courses being 14-21 d. Preparation should be introduced under ultrasound control by introducing 0.5-4%-ethoxysclerol solution at the quantity of 0.5-1 ml/ml nodal volume in case of nodal-type neoplasm. In case of cystic neoplasm - at the quantity of 3-5 ml. Introduction should be fulfilled after liquid aspiration only. One day before the onset of every course of sclerotherapy Movalis 7.5 mg should be prescribed once daily after meals for 5-10 d. The innovation enables to avoid surgical therapy, and, also, increase patients' quality of life due to carrying out sclerosing along with interrupting the pronounced pain syndrome and in some cases heal the disease mentioned.

EFFECT: higher efficiency of therapy.

2 cl, 4 ex

FIELD: chemical-pharmaceutical industry, biochemistry, medicine.

SUBSTANCE: invention relates to a liposome directly effecting on αvβ3-integrin receptors and comprising cationic amphiphilic substance including 1,2-dioleoyloxy-3-(N,N,N-trimethylammonium)propane chloride, neutral lipid, lipid with a direct effect having domain with a direct effect and hydrophobic domain bound with domain of a direct effect, and nucleic acid forming complex with cationic lipid. Cationic lipid presents in the amount from about 1 to about 50 molar % and indicated lipid with a direct effect presents in the amount from about 1 to about 20 molar % wherein molar percents are calculated as measured for the total number of lipid moles in liposome. Domain with a direct effect comprises a nonpeptide antagonist of αvβ3-integrin comprising 4-[2-(3,4,5,6-tetrahydropyrimidin-2-ylamino)ethyloxy]-benzoyl-2-(S)-aminoethylsulfonamino-β-alanine (compound 10) bound covalently with hydrophilic domain by amide bond. Also, invention relates to a method for inhibition of angiogenesis and involving administration to a patient needing in inhibition of angiogenesis a liposome in the therapeutically effective dose that directly effects on αvβ3-integrin receptors and comprising nucleic acid that is able to express a protein or peptide suppressing angiogenesis.

EFFECT: valuable properties of system.

27 cl, 2 tbl, 18 dwg, 8 ex

FIELD: organic chemistry, chemical technology, medicine, oncology, pharmacy.

SUBSTANCE: invention relates to novel derivative of variolin B of the general formula (I) or their pharmaceutically acceptable salts possessing antitumor activity. In the general formula (I) radical R1 means aromatic group representing aromatic group representing phenyl optionally substituted with nitro-group, amino-group or alkyl-substituted amino-group, or aromatic group represents 5-6-membered heterocycle with two nitrogen atoms or sulfur atom as heteroatoms optionally substituted with (C1-C12)-alkyl, -OH, unsubstituted amino-group or amino-group substituted with (C1-C4)-acyl, phenyl-(C1-C4)-alkyl wherein phenyl group can be substituted with -OR1, or (C1-C12)-alkylthio-group, (C1-C12)-alkyl- or phenylsulfonyl, (C1-C12)-alkyl- or phenylsulfinyl or -OR1 wherein R1 is chosen from (C1-C12)-alkyl or phenyl; R2 represents hydrogen atom; R3 represents oxo-group when a dotted line is between nitrogen atom to which R2 is bound and carbon atom to which R3 is absent, or R2 is absent when R3 represents optionally protected amino-group wherein a substitute is chosen from (C1-C4)-acyl, phenylsulfonyl and (C1-C4)-alkylphenylsulfonyl when a dotted line forms a double bond between nitrogen atom to which R2 is bound and carbon atom to which R2 is bound; R4 represent hydrogen atom. Also, invention relates to a method for synthesis of compounds of the invention and to intermediate substances for their realization. Also, invention relates to a pharmaceutical composition based on variolin B derivatives.

EFFECT: improved method of synthesis, valuable medicinal property of compounds and pharmaceutical composition.

22 cl, 5 sch, 1 tbl, 50 ex

FIELD: organic chemistry, medicine, oncology, biochemistry, pharmacy.

SUBSTANCE: invention relates to novel tricyclic compounds, their pharmaceutically acceptable salts and solvates useful for inhibition of activity of farnesyl-protein-transferase. Invention describes compound of the formula (1.0): or its pharmaceutically acceptable salt or solvate wherein one among a, b, c and d means nitrogen atom (N) or -N+O-, and other a, b, c and d mean carbon atom and wherein each carbon atom comprises radical R1 or R2 bound to indicated carbon atom; or all a, b, c and d mean carbon atom wherein each carbon atom comprises radical R1 or R2 bound to indicated carbon atom; broken line (- - -) means optional binds; X means N or -CH when optional bond is absent, and it means carbon atom (C) when optional bond presents; when optional bond between carbon atom 5 and carbon atom 6 presents then only a single substitute A presents bound with carbon atom 5, and only a single substitute B presents bound with carbon atom 6, and A and B fifer from hydrogen atom (H); if optional bind between carbon atom 5 and carbon atom 6 is absent then two substitutes A present bound with carbon atom 5, and two substitutes B bound with carbon atom 6 wherein at least one of two substitutes A or one among two substitutes B mean H and wherein at least one of two substitutes A or one of two substitutes B has value distinct from H, and other radical are described in the invention claim. Also, invention disclosed a pharmaceutical composition comprising such compounds, a method for inhibition of anomalous growth of cells and methods for treatment of proliferative diseases as cancer.

EFFECT: valuable medicinal properties of compounds and pharmaceutical composition, improved method of treatment.

52 cl, 2 tbl, 505 ex

FIELD: medicine, biochemistry, pharmacy.

SUBSTANCE: invention describes dipeptide-nitrile inhibitors of cathepsin K, their pharmaceutically acceptable salts or their esters that are used in therapeutic or prophylaxis treatment of disease of morbid state mediated by cathepsin K.

EFFECT: valuable medicinal properties of inhibitors.

3 cl, 11 ex

FIELD: organic chemistry, biochemistry, medicine, pharmacy.

SUBSTANCE: invention describes compound of the formula (U): or its pharmaceutically acceptable salt wherein X is chosen from -NR1, sulfur atom (S); Y1 and Y2 represent oxygen atom (O); Z represents O; m = 0 or 1; A is chosen from a direct bond, (C1-C6)-alkyl; R1 is chosen from hydrogen atom (H), alkyl; R3 and R6 are chosen independently from H, alkyl, halogenalkyl, heteroalkyl, cycloalkyl, aryl, cycloalkyl-alkyl, cycloalkyl-heteroalkyl, heterocycloalkyl-alkyl, alkylaryl, heteroaryl, arylalkyl, aryl-heteroalkyl, heteroaryl-alkyl, heteroaryl-heteroalkyl or heterocycloalkyl; R4 is chosen from H, alkyl; R5 represents a bicyclic or tricyclic group comprising two or three ring structure wherein each of that comprises from 3 to 7 ring atoms chosen independently from cycloalkyl, aryl, heterocycloalkyl or heteroaryl wherein each ring structure is joined with the next ring structure through a direct bond, through -O-, through -S-, through (C1-C6)-alkyl, through (C1-C6)-heteroalkyl, through (C1-C6)-alkynyl, through carboxy-(C1-C6)-alkyl, or it is condensed with the next ring structure wherein heteroalkyl represents heteroatom-substituted alkyl comprising one heteroatom chosen from N, O and S. Also, invention describes compounds of formulae (Ib), (Ic) and (Id) given in the invention description, pharmaceutical composition and using these compounds in preparing a medicine for using in treatment of disease or state mediated by one or more enzymes representing metalloproteinase. Represented compounds are useful as inhibitors of metalloproteinases and especially as inhibitors of MMP12.

EFFECT: valuable medicinal and biochemical properties of compounds and pharmaceutical composition.

17 cl, 3 tbl, 17 ex

FIELD: organic chemistry, biochemistry, medicine, pharmacy.

SUBSTANCE: invention describes compound of the formula (I): wherein X represents -NR1; Y1 and Y2 represent oxygen atom (O); Z is chosen from -SO2N(R6), -N(R7)SO2; m = 1 or 2; A is chosen from a direct bond, (C1-C6)-alkyl; R1 represents hydrogen atom (H); each R2 and R3 is chosen independently from H, alkyl, aryl, alkylaryl, arylalkyl; each R4 is chosen independently from H, (C1-C3)-alkyl; R6 is chosen from H, alkyl, aryl, heteroaryl, alkylaryl, alkyl-heteroaryl, arylalkyl, heteroaryl-alkyl; R2 and R6 can join to form a ring comprising up to 7 ring atoms, or R3 and R6 can join to form a ring comprising up to 7 ring atoms, or R4 and R6 can join to form a ring comprising up to 7 ring atoms; R5 represents monocyclic, bicyclic or tricyclic group comprising one or two ring structures wherein each of that comprises up to 7 ring atoms chosen independently from cycloalkyl, aryl, heterocycloalkyl or heteroaryl and possibly substituted; when R5 represents bicyclic group then each ring structure is bound with the next ring structure through a direct bond, through -O-, through (C1-C6)-alkyl or condensed with this next ring structure; R7 is chosen from (C1-C6)-alkyl. Also, invention describes compound of the formula (II) given in the description, pharmaceutical compositions and using compound of the formula (I) or the formula (II) in preparing a medicine for using in treatment of disease or state mediated by one or more enzymes and representing metalloproteinase. Represented compounds are useful as inhibitors of metalloproteinases and especially as inhibitors of MMP12.

EFFECT: valuable medicinal and biochemical properties of inhibitors and pharmaceutical compositions.

20 cl, 3 tbl, 6 ex

FIELD: medicine, oncology.

SUBSTANCE: method involves using an antitumor preparation prepared by using the apparatus-program complex (APC) "IMEDIS-TEST". Method involves blood sampling in a patient, its diluting in physiological solution in the ratio 1:1 followed by addition of the preparation "MP-antiprotein-blocker" and diluted blood in contour APC "IMEDIS-TEST". Then method involves effect with this preparation on blood in regimen "transfer" followed by returning blood in patient body. Then method involves carrying out treatment involving detoxification of body in 1, 14, 21, 28, 35 and 42 days of treatment using Glauber's salt (sodium sulfate decahydrate) as a laxative agent and also cleansing enema and fractional dose of citrus juice (40-50 ml) in the ratio 1:1 with water for 10-12 h and aqueous-turpentine bath. Then method involves carrying out the monocarrot diet for 12 days from 2-d to 13-th day of treatment inclusively; basic nutrition - each 6 days after detoxification comprising: a dose of olive oil before eating (30-35 g) with lemon juice in the ratio 1:1, in 25-30 min a dose of 100-120 ml of carrot-beet juice in the ratio 1:1, in 25-30 min a dose of 200-250 ml kefir infusion prepared from crude buckwheat grain, and a dose of 0.3 g of pepsin or 10-15 ml of pepsidil, a dose of 3.0-5.0 ml of horse radish roots infusion with lemon juice, a dose of 50-60 ml of medicinal herbs aqueous species. Method provides antitumor effect based on disturbance of cancer cells nutrition and normalization of body normal cells nutrition and recovery of metabolism and detoxification of the patient body. Invention can be used in treatment of malignant tumors of different localization and development stage.

EFFECT: enhanced effectiveness of diagnosis and treatment.

1 tbl, 2 ex

FIELD: medicine, oncology, chemical-pharmaceutical industry.

SUBSTANCE: invention relates to a pharmaceutical composition designated for treatment of tumors and tumor metastasis. The composition comprises: (i) at least one antibody or its functionally intact derivative comprising a binding site that binds with the epitope ErbB1(Herl1) of receptor and (ii) at least one agent inhibiting angiogenesis being optionally in common with a pharmaceutically acceptable carrier, diluting agent or excipient used in the combined therapy in treatment of tumors and tumor metastasis. Using the proposed composition can result to the possible synergetic enhancing inhibitory effect of each specific therapeutic agent with respect to inhibition of tumor cells proliferation and providing the enhanced effective treatment as compared with individual agents using separately.

EFFECT: enhanced effectiveness of therapy.

25 cl, 1 ex

FIELD: medicine, oncogynecology.

SUBSTANCE: it is necessary to carry out expanded uterine extirpation and intrasurgical radiation therapy (ISRT). In women of reproductive age at squamous cell forms of uterine cervix cancer before the stage of expanded uterine extirpation one should fulfill ovarian transposition by fixing them in the upper departments of lateral canals of abdominal cavity to provide their functional safety and integrity of vascular peduncle. On finishing the stage of expanded uterine extirpation it is important to form the field of irradiation that includes vaginal stump and perivaginal fiber by restricting the organs of small pelvis and abdominal cavity against irradiation region. Irradiation should be carried out due to distance technique by providing the dosage of 15 Gy in the preset area. On finishing the ISRT seance it is necessary to conduct peritonization of small pelvis. The innovation enables to decrease the frequency of postsurgical complications that take place while ISRT procedure.

EFFECT: higher efficiency of therapy.

1 cl, 2 ex

FIELD: medicine, oncology, radiology.

SUBSTANCE: the suggested thermochemoradiation treatment should be fulfilled in three stages at intervals between each of them being 10-14 d: during the 1st stage it is necessary to carry out distance gamma-therapy daily at fractionating the dosage during 1-3 d per 4 Gy, then during 4-22 d per 2 Gy up to TFD being 50 isoGy, radiosensitization with 5-fluorouracil daily at the dosage of 125 mg intravenously at flow-type technique 30 min before the séance of radiation treatment and local thermotherapy with transrectal sensor once/2 d, every other day, just before gamma-therapy; during the 2nd stage it is necessary to conduct radiosensitization and local thermotherapy similarly, as it was during the first stage, as for irradiation it should be carried out as intracavitary gamma-therapy daily per 3 Gy up to TFD being 18-24 Gy; during the 3d stage one should fulfill radiosensitization with fluorouracil as during the first and second stages and carry out distance gamma-therapy daily per 2 Gy so that TFD from all three stages should achieve 74 isoGy.

EFFECT: higher efficiency of therapy.

3 ex

FIELD: medicine, oncology.

SUBSTANCE: the present innovation deals with complex therapy of mammary gland cancer at T1-2NO-1MO. The method includes chemo- and radiation therapy and operation procedure. Moreover, in post-surgical period, before the onset of radiation therapy course it is necessary to sample 200 ml patient's blood and due to centrifuging technique isolate autoplasma. One should place 20 ml autoplasma and chemopreparations into the first vial, into the second vial - remained blood cells and autoplasma. Vials should be separately incubated for 40 min at 37° C, then during the first day of radiation therapy before the onset of the seance one should introduce the half of autoplasma volume incubated with chemopreparations from the first vial into the ducts of operated mammary gland, as for the remained part of autoplasma incubated with chemopreparations, from the first vial it should be introduced into the site of surgical withdrawal of drainage tube. Blood incubated with chemopreparations from the second vial should be reinfused intravenously by drops. The innovation is of low toxicity and enables to carry out complex organ-saving therapy in short terms, decrease the frequency of local relapses and remote metastases, the number of radiation reactions and complications.

EFFECT: higher efficiency.

2 ex

FIELD: methods and devices for treatment of oncology patients using sources of ionizing radiation, namely, technology of pre-irradiation preparation and irradiation during intracavitary and interstitial radiotherapy.

SUBSTANCE: method for pre-irradiation preparation and irradiation includes positioning the patient on treatment-diagnostics table, inserting into cavity to be irradiated of hollow applicators with imitators of ionizing radiation sources, controlling position thereof relatively to target being irradiated with usage of x-ray television device, building of dosimetric plane and irradiation, while applicators inserted into cavity being irradiated are connected to treatment-diagnostics table, x-ray radiography is performed with output of image onto monitor of viewing station of x-ray television device, image via the interface is transported into planning system, dosimetric plane of irradiation is computed, which is then exported into system for controlling device and irradiation procedure is performed. Treatment-diagnostics table has frame, two supporting posts with overhung table top mounted on them, consisting of a pelvic-dorsal and two extending leg sections, connected to pelvic-dorsal section by means of twin joints. For connection of applicator table is provided with mounting pillar.

EFFECT: possible irradiation directly near apparatus without moving the patient during x-ray control of position of applicators and, therefore, increased quality of radiotherapy and therapeutic efficiency, decreased duration of pre-irradiation preparation.

2 cl, 3 dwg

FIELD: medicine, in particular, radiotherapy.

SUBSTANCE: during irradiation of oncology patients on cobalt distance apparatuses dose field is formed by injecting topographic-anatomic information of patient into dose planning system and generating with its consideration of main dose field on basis of results of calculations of main dose field, dose deficiency area is located within limits of target and iso-centers of additional dose fields are positioned therein, while width of radiation beams, generating additional dose fields, is less than width of beam of main dose fields 1,5-2,5 times, while value of dose of main field is 0,7-0,85 of resulting dose within limits of target.

EFFECT: possible generation of dose field with minimal possible dose change on target while simultaneously decreasing radiation loads on normal tissues and skin.

2 dwg, 1 ex

FIELD: medicine, in particular, oncology.

SUBSTANCE: in accordance to method, thermo-radio-therapy of malignant tumors is performed in form of split course in mode of enlarged dynamic fractioning of dose in 6 fractions of 4 Gy and 8 fractions of 2 Gy in first course, and 6 fractions of 4 Gy and 3 fractions of 2 Gy in second course in conjunction with hyper-thermal effect in the same day when radio-therapy is performed.

EFFECT: increased apparent counter-tumor local effect.

2 ex

FIELD: medicine, namely, medicinal use of radiation, possible use for determining dose really received by pathologic focus having absorbed open radioactive nuclide.

SUBSTANCE: method for verification of dose during medicinal usage of open radioactive nuclides includes measuring intensiveness of radiation, with consideration of changes in radiation source activity in time, during that, by means of tissue-equivalent phantom, original intensiveness of radiation of open radionuclide is measured immediately prior to injecting it into organism of patient as well as average intensiveness of radiation from focuses having absorbed radionuclide, and after that individual relative dose of open radionuclide injected into pathologic focuses is computed using formula

where Dn/o - value of relative dose in %, Io - original intensiveness of radiation at the moment of injection of radionuclide, In - average intensiveness of radiation from focuses at day or hour of measurement of n, B0 and Bn - background values of radiation intensiveness at the moment of injection of radionuclide and at the day of measurement, respectively, k - coefficient of daily or hourly decomposition of radionuclide, n - number of days or hours having passed since the moment of injection of radionuclide.

EFFECT: invention allows verification of relative dose in most precise and individual manner.

3 ex

FIELD: medical facilities.

SUBSTANCE: device can be used as a tool for malignant tumors surgery. Device for radionuclide surgery has gamma radiation detector, collimator and handle. Wire of detector is connected with measuring unit. Gamma radiation detector is fixed in metal tip with sharpened side edge, which passes in plane being perpendicular to optical axis of gamma radiation detector. Detector is made in form of semiconductor crystal; two collimators adjoin opposite surfaces of crystal. Collimators have cells which pass in parallel to optical axis of gamma detector. Measuring unit has electronic circuit with sonic signal source.

EFFECT: ability of reaching area of lesion for removing it.

4 cl, 2 dwg

FIELD: medicine.

SUBSTANCE: device belongs to wide spectrum of influence devices, which is able to make prophylactic and medicinal influence onto human body; in particular, it can be used for destroying benign and malignant tumors and other concentrated formations. Device for making physiotherapeutic effect has control unit and influence localization unit connected with influence localization area. It also has hard base and unit for movement along x, y and z coordinates. Physiotherapeutic device is made in form of frame mounted onto hard base for shift in linear coordinates x, y and z, and n physiotherapeutic influence sources. The sources are disposed along perimeter of frame, which frame is connected mechanically with corresponding outputs of shift unit along coordinates x, y and z. Inputs o shift unit are connected with corresponding outputs along coordinates x, y and z of control unit. Corresponding inputs of control unit are connected with additional outputs of shift unit along coordinates x, y and z. Control input of control unit is connected with output of influence localization unit.

EFFECT: improved efficiency of physiotherapeutic effect; reduced negative reactions of organs and tissues surrounding the area.

13 cl, 5 dwg

FIELD: medicine.

SUBSTANCE: method involves administering Wobenzyme combined with brachytherapy with radiomodification and transpupillary thermotherapy or combined with isolated transpupillary thermotherapy. When combined with brachytherapy with radiomodification, Wobenzyme is given 2 days before brachytherapy at a dose of 3 pills 3 times a day with the exception of 8 h before fixation and removal of β-applicator. Next to it, Wobenzyme is given at a dose of 4-6 pills 3 times a day during 3 months. Then, the dose is reduced by 2 pills every month at the fourth, fifth and sixth months. Adjuvant transpupillary thermotherapy is carried out 6 months later after brachytherapy. Wobenzyme is given at a dose of 2-3 pills 3 times a day 2 days before transpupillary thermotherapy. Then, the dose is 4-6 pills 3 times a day during 2 months with following dose reduction by 3 pills every month to prophylactic dose of 1 pill a day. When carrying out isolated transpupillary thermotherapy, Wobenzyme is given in the same mode that it was the case when carrying out adjuvant transpupillary thermotherapy after brachytherapy. To prevent metastasis occurrence, Wobenzyme administration is continued at a dose of 1 pill 7 days every month during the first year and at a dose of 1 pill 3 days every month during the second observation year.

EFFECT: accelerated resorption processes; reduced risk of radiation treatment complications.

FIELD: medicine, surgery.

SUBSTANCE: it is necessary to create the fluctuations of intestinal content till peristaltics renewal. Moreover, one should apply a probe into intestinal lumen to fill it with liquid through a protruding end followed by clamping. It is necessary to develop fluctuations of liquid inside the probe at acceleration being about 0.2-0.6 m/sq. cm. Protruding part of the probe should be placed into special device for periodic clamping the probe's walls at the following frequency: 2 cycles of clamping/unclamping/sec during the whole period of the probe's location in intestine. The innovation enables to decrease intoxication in patients with intestinal paresis.

EFFECT: higher efficiency of therapy.

1 ex, 1 tbl

Up!